Bioenvision - 500 Beiträge pro Seite

[Macros]

Bioenvision hat in den letzten Tagen an Interesse gewonnen und zwar durch die Aufnahme in den NASDAQ Biotechnology Index.
Die Aktie hatte danach einen rasanten Kursanstieg ist aber auch schnell wieder am Ausgangspunkt angekommen.
Der Wert hat meiner Ansicht Potenzial.


Bioenvision`s primary focus is the development and distribution of compounds and technologies for the treatment of cancer. Bioenvision has a broad pipeline of products for the treatment of cancer, including: Clofarabine (in co-development with ILEX Oncology, Inc.), Modrenal(R) (for which Bioenvision has obtained regulatory approval for marketing in the United Kingdom for the treatment of post-menopausal breast cancer following relapse to initial hormone therapy), and other products in clinical trials. Bioenvision is also developing anti-infective technologies, including the OLIGON technology; an advanced biomaterial that has been incorporated into various FDA approved medical devices. For more information on Bioenvision please visit our Web site at www.bioenvision.com.

[Macros]

Clofarabine Achieves High Response Rates in Acute Myeloid Leukaemia -AML-; Three Fold Increase in Response Rates Compared with Current Standard of Care



SAN DIEGO--(BUSINESS WIRE)--Dec. 6, 2004--Bioenvision, Inc. (Nasdaq: BIVN) announced today that results presented at the 46th American Society of Haematology Meeting (ASH) showed that clofarabine achieved a three fold greater overall response rate than current best standard of care in older patients with Acute Myeloid Leukaemia (AML) who were unsuitable for intensive chemotherapy.

In a European multi-center study, clofarabine was administered first line, as a monotherapy, to 30 patients over 60 years of age with AML and 13 (43%) patients achieved a complete response (CR); 4 (13%) patients achieved a complete response without full platelet recovery (CRp); and 3 (10%) achieved a partial remission (PR), thus giving an overall response rate of 66%. This compared favorably with the current best standard of care, low-dose ara-C, which achieved a CR rate of 17% in the AML 14 Trial conducted by the UK National Cancer Research Institute. The duration of remission observed with clofarabine was also durable with the interim follow-up at a median of at least 6 months.

"Clofarabine is one of the most active agents in AML," said Professor Alan Burnett, Chairman of the UK National Cancer Research Institute Hematological Oncology Study Group and principal investigator of the European adult AML clinical studies.

Presenting initial results of clofarabine in combination with daunorubicin as a first line regimen for adult AML, Professor Burnett also stated "his early experience had been very encouraging." He proposed a program of national and international studies to evaluate further clofarabine`s potential both as a single agent and in a variety of combinations for the treatment of AML.

Clofarabine was previously granted orphan drug designation for the treatment of adult and pediatric ALL and AML by both the FDA and the EMEA. In the U.S., orphan drug status extends seven years of market exclusivity for the orphan drug indication following the FDA`s marketing approval. In Europe, this designation provides European marketing exclusivity for 10 years.

About Clofarabine

Clofarabine is a next generation of the drug class purine nucleoside analogs which all inhibit DNA production necessary for cancer cell growth. Bioenvision, Inc. (Nasdaq:BIVN) sub-licensed ILEX the right to develop and market clofarabine for human cancer indications in the United States and Canada. Bioenvision is entitled to milestone payments tied to the development of the compound and is entitled to royalties on North American sales. As is its exclusive right, Bioenvision is developing clofarabine in the rest of the world. Bioenvision originally obtained clofarabine development and commercialization rights under patents held by Southern Research Institute.

[Macros]

Konsolidierung dürfte bald abgeschlossen sein..
Charttechnik steht schon auf kaufen. Schätze das Bioenvision bei Freundlichen Marktumfeld wieder über 10$ ist in 2 Wochen.

[Macros]

Es sieht so aus als heute Bioenvision im Fokus stehen wird. Ich habe keine Nachrichten sehen können, aber im Vorhandel legt die Aktie schon 15% hin unter nicht schlechtem Umsatz. (Insider vieleicht)
Die 10$ könnten heute Geschichte werden. Aber Mann soll den Tag ja nicht vor dem Abend loben.


Aber es ist ja eh egal.. bin ja eh der einzige der sich für meine Aktien hier im Forum Interessiert


Grüße an diejenigen die meine Threads auch ab und zu lesen oder sogar investiert haben

Macros

[Macros]

Hier noch die letzte Kaufempfehlung die gerne auf sogenannte Experten hören.
Schon etwas her, aber macht ja nix.

16.11.2004 17:21:
Update Bioenvision Inc.: Buy

Die Analysten von Oppenheimer bewerten in ihrer Analyse vom Dienstag, 16. November 2004 die Aktie von Bioenvision neu mit dem Rating "Buy". Das Kursziel für die Aktie liegt momentan bei 16 $.


Gruss
Macros

[therman]

Before the Bell - Bioenvision rises 16.7 percent
Wed Dec 29, 2004 08:07 AM ET
NEW YORK, Dec 29 (Reuters) - Shares of Bioenvision Inc. (BIVN.O: Quote, Profile, Research) surged 16.7 percent before the bell on Wednesday.
U.S. regulators said Tuesday they approved a new cancer drug from Genzyme Corp. (GENZ.O: Quote, Profile, Research) for treating a type of childhood leukemia. The drug, Clolar, was developed by Bioenvision, which sold North American rights to the drug to Ilex Oncology Inc. Ilex was acquired by Genzyme earlier this month.

On the Inet electronic brokerage system, Bioenvision jumped $1.42 to $9.89 from Tuesday`s close of $8.47 on Nasdaq.

[Macros]

Danke therman

Also doch nicht ohne Grund

Gruss
Macros

[wildkatz]

Clofarabine Receives FDA Approval for Most Common Pediatric Leukemia
29.12.2004 15:56:00



Clofarabine Receives FDA Approval for Most Common Pediatric Leukemia


Business Editors/Health/Medical Writers

NEW YORK--(BUSINESS WIRE)--Dec. 29, 2004--Bioenvision, Inc. (Nasdaq:BIVN) announced today that the U.S. Food and Drug Administration has granted marketing approval for Clofarabine for the treatment of children with refractory or relapsed Acute Lymphoblastic Leukemia (ALL).
Clofarabine is indicated by FDA for the treatment of pediatric patients 1 to 21 years of age with relapsed or refractory ALL after at least two prior regimens.
According to the American Cancer Society, Leukemia is the most common childhood cancer with an incidence rate of approximately 3,600 new cases every year in the US. The FDA`s approval follows the recommendation made by the Oncology Drug Advisory Committee (ODAC) in Washington on Dec. 1st 2004.
Clofarabine was previously granted orphan drug designation for the treatment of adult and pediatric ALL and AML, both in the US and in Europe. In the U.S., orphan drug status extends seven years of market exclusivity for the orphan drug indication following the FDA`s marketing approval. The FDA also recently granted an additional six months market exclusivity to Clofarabine under the Best Pharmaceuticals for Children Act. In Europe, this designation provides European marketing exclusivity for 10 years.
Dr Christopher Wood Chief Executive Officer of Bioenvision stated, "this is a fantastic milestone in the development of Clofarabine. Following the exciting data that was released at the American Society of Hematology (ASH) at the beginning of December in both the adult and pediatric settings, more people who are involved in the treatment of acute leukemias, are realizing how vital Clofarabine is as part of their treatment options."
"We look forward to more children being given the opportunity to benefit from Clofarabine in the US and are very confident that this momentum will help us bring these benefits to many other children in Europe and other parts of the world."

[wildkatz]

Hallo,

wenn man sich den Tread hier so anschaut könnte man meinen, dass sich kein Mensch für Bioenvision interessiert (mit wenigen Ausnahmen). Dabei ist Bioenvision doch so ein interessantes Investment.

Hätte allerdings schon erwartet dass bei so einer Nachricht ein bischen mehr geht.
9 Prozent heute im Amiland ist so toll auch wieder nicht.

Naja, vieleicht gehts ja in den nächsten Tagen noch a weng richtung Norden...

[Macros]

Hallo,

Hätte mir auch mehr erwartet von gestern. Hoffe das gestern die Zocker mit abgesprungen sind nachdem es stetig nur bergab ging.

Freut mich jedenfalls das ich nicht der einzige bin der sich für dieses Investment interessiert.

Mal schaun in welche Richtung es in den nächsten Tagen geht.

Gruss
Macros